INTRODUCTION

Blinatumomab (brand name Blincyto) is a bispecific T-cell engager (BiTE) that links anti-CD3 single-chain variable fragment (scFV) and anti-CD19 scFV to recognize malignant B cells and T cells. Blinatumomab works by activating T cells to exert cytotoxic activity on the target cells. Blinatumomab is used in the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

This plasmid is designed for expressing Blinatumomab in mammalian cells such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-36
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Blinatumomab
Brand Names: Blincyto
Classification: Fusion scFvs, monoclonal antibody (mAb)
Target: CD19, CD3
Amino Acid Sequence: Identical to DB09052

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

Zugmaier G, Klinger M, Schmidt M, Subklewe M. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies. Mol Immunol. 2015 Oct;67(2 Pt A):58-66.

Contact Us